Program
GR2301
A development code. Also written as “GR2301 injection”.
Its studies are mostly in Vitiligo, led by Chongqing Genrix Biopharmaceutical.
Furthest: phase 2, since May 25, 20264 company-led studies, 4 open or runningNext primary completion: Jul 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Genrix Biopharmaceutical | 44 open or running | phase 2since May 25, 2026 | Sep 17, 2025 | Jul 2027phase 1 · NCT07647224 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 17, 2025First study: phase 1 study in Single Ascending DoseFirst studyNCT07190716 · 36 planned · China
- May 24, 2026Phase 1 study in Multiple DoseNCT07647224 · 36 planned · China
- May 25, 2026Phase 2 study in VitiligoPhase 2 reachedNCT07647237 · 116 planned
- Nov 5, 2026Phase 2 study in VitiligoNCT07930039 · 120 planned
Ahead
- Jul 2027Primary completion: phase 1 study in Multiple DoseNCT07647224
- May 2028Primary completion: phase 2 study in VitiligoNCT07930039
- Jun 2028Primary completion: phase 2 study in VitiligoNCT07647237
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07930039Vitiligo | 2 | Not yet recruiting | May 2028 | 120 |
| NCT07647237Vitiligo | 2 | Not yet recruiting | Jun 2028 | 116 |
| NCT07647224Multiple Dose · China | 1 | Not yet recruiting | Jul 2027 | 36 |
| NCT07190716Single Ascending Dose · China | 1 | Not yet recruiting | May 30, 2026 | 36 |
How it is read
Names in the registry
- “GR2301 injection”, 4 entries
Codes read as this program: GR2301.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.